TFCP2 (transcription factor CP2) is a sequence-specific DNA-binding transcription factor that regulates RNA polymerase II-dependent gene expression 1. It functions as a transcriptional activator, binding to cis-regulatory elements in diverse cellular and viral promoters and participating in protein-containing complexes including the stage selector protein (SSP) complex for erythroid gene regulation. In cancer biology, TFCP2 demonstrates context-dependent roles. It acts as a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer, and breast cancer, while functioning as a tumor suppressor in melanoma 1. In colorectal cancer, oncogenic KRAS activates TFCP2 to upregulate proadipogenic factors BMP4 and WNT5B, transforming carcinoma-associated fibroblasts into lipid-rich cells that promote angiogenesis and tumor progression; genetic or pharmacologic TFCP2 neutralization reduces angiogenesis and improves survival in mouse models 2. In melanoma, TFCP2 cooperates with YAP1 in a transcriptional complex downstream of TRAF6 to enhance PD-L1 expression, promoting immune evasion; TRAF6 inhibition reduces PD-L1 and enhances anti-tumor immunity 3. Clinically, TFCP2 rearrangements—particularly FUS/EWSR1-TFCP2 fusions—define a rare, aggressive rhabdomyosarcoma subtype with poor prognosis (28% 3-year overall survival), predominantly affecting young adults with craniofacial bone involvement 4. These fusion-driven tumors exhibit ALK overexpression and CDKN2A/MTAP co-deletions, identifying potential therapeutic vulnerabilities to ALK and PRMT5 inhibitors 5.